Over 65 companies advance 75+ COPD drugs in clinical trials, signaling major progress in treatment options.

More than 65 companies are actively developing over 75 drugs for chronic obstructive pulmonary disease (COPD), reflecting a robust pipeline of next-generation therapies. Key players like Amgen, AstraZeneca, Sanofi, and GSK are advancing treatments through various clinical trial phases, including promising biologics targeting inflammation and immune pathways. Recent successes include AstraZeneca's Tozorakimab showing positive Phase III results, and Bambusa Therapeutics initiating trials for a novel bispecific antibody. This expanding pipeline aims to improve COPD management beyond current bronchodilators and corticosteroids, with a focus on early diagnosis and combination therapies to enhance patient outcomes.